Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 11.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,906 shares of the biopharmaceutical company’s stock after purchasing an additional 190 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Alnylam Pharmaceuticals were worth $524,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of ALNY. Allspring Global Investments Holdings LLC raised its stake in shares of Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $26,000. Hollencrest Capital Management purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $29,000. Altitude Crest Partners Inc. purchased a new stake in Alnylam Pharmaceuticals during the 1st quarter worth approximately $30,000. Finally, Washington Trust Advisors Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $42,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $198.00 to $370.00 in a research report on Friday, August 16th. JPMorgan Chase & Co. upped their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a report on Monday, August 26th. Raymond James increased their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Cantor Fitzgerald reiterated a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Finally, Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $298.09.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $248.79 on Thursday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The stock has a market capitalization of $32.09 billion, a P/E ratio of -94.96 and a beta of 0.39. The firm’s 50-day moving average is $273.83 and its two-hundred day moving average is $236.76. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same quarter in the previous year, the company earned $1.15 earnings per share. The business’s revenue was down 33.3% on a year-over-year basis. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.